World Markets

Dr. Reddy's Labs Unveils Renvela Generic Sevelamer Carbonate In U.S

An image of a pen pointing at a stock chart
Credit: Shutterstock photo

(RTTNews.com) - Dr. Reddy's Laboratories Ltd. (RDY, DRREDDY) announced Thursday the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets.

It is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration.

Renvela is a trademark of French drug giant Sanofi (SNYNF, SNY).

Dr. Eddy's noted that the Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent twelve months ending in October 2018, according to IMS Health.

Dr. Reddy's Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90.

Read the original article on RTTNews (http://www.rttnews.com/2965465/dr-reddy-s-labs-unveils-renvela-generic-sevelamer-carbonate-in-u-s.aspx)

For comments and feedback: contact editorial@rttnews.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks Economy

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More